These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 23300537)

  • 1. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
    Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
    PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
    Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
    Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.
    Wang Q; Zhang Y; Zhu J; Zheng H; Chen S; Chen L; Yang HS
    Signal Transduct Target Ther; 2020 Aug; 5(1):153. PubMed ID: 32843616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.
    Shin DH; Lee HJ; Min HY; Choi SP; Lee MS; Lee JW; Johnson FM; Mehta K; Lippman SM; Glisson BS; Lee HY
    J Natl Cancer Inst; 2013 Oct; 105(20):1558-70. PubMed ID: 24092920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807.
    Dinchuk JE; Cao C; Huang F; Reeves KA; Wang J; Myers F; Cantor GH; Zhou X; Attar RM; Gottardis M; Carboni JM
    Endocrinology; 2010 Sep; 151(9):4123-32. PubMed ID: 20610571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
    Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
    Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Src tyrosine kinases in experimental pulmonary hypertension.
    Pullamsetti SS; Berghausen EM; Dabral S; Tretyn A; Butrous E; Savai R; Butrous G; Dahal BK; Brandes RP; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Rosenkranz S; Schermuly RT
    Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1354-65. PubMed ID: 22516066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
    Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE
    Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.
    Sabbatini P; Rowand JL; Groy A; Korenchuk S; Liu Q; Atkins C; Dumble M; Yang J; Anderson K; Wilson BJ; Emmitte KA; Rabindran SK; Kumar R
    Clin Cancer Res; 2009 May; 15(9):3058-67. PubMed ID: 19383820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
    Hou X; Huang F; Macedo LF; Harrington SC; Reeves KA; Greer A; Finckenstein FG; Brodie A; Gottardis MM; Carboni JM; Haluska P
    Cancer Res; 2011 Dec; 71(24):7597-607. PubMed ID: 22042792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.
    Alam MM; Lee SC; Jung Y; Yun HJ; Min HY; Lee HJ; Pham PC; Moon J; Kwon DI; Lim B; Suh YG; Lee J; Lee HY
    Oncotarget; 2015 Dec; 6(38):40598-610. PubMed ID: 26515601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
    Carboni JM; Wittman M; Yang Z; Lee F; Greer A; Hurlburt W; Hillerman S; Cao C; Cantor GH; Dell-John J; Chen C; Discenza L; Menard K; Li A; Trainor G; Vyas D; Kramer R; Attar RM; Gottardis MM
    Mol Cancer Ther; 2009 Dec; 8(12):3341-9. PubMed ID: 19996272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
    Chang AY; Wang M
    BMC Cancer; 2013 May; 13():267. PubMed ID: 23721490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
    Nautiyal J; Banerjee S; Kanwar SS; Yu Y; Patel BB; Sarkar FH; Majumdar AP
    Int J Cancer; 2011 Feb; 128(4):951-61. PubMed ID: 20473900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
    Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
    Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
    Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
    Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.
    Huang F; Chang H; Greer A; Hillerman S; Reeves KA; Hurlburt W; Cogswell J; Patel D; Qi Z; Fairchild C; Ryseck RP; Wong TW; Finckenstein FG; Jackson J; Carboni JM
    Mol Cancer Ther; 2015 Feb; 14(2):620-30. PubMed ID: 25527633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.